...DEERFIELD Ill. Nov. 1 2011 /- Takeda Global Res...Currently the FDA is reviewing the new drug applications (NDA) for th...According to the International Diabetes Federation a staggering 285 m... As recent figures indicate that diabetes continues to be a serious gl...

DEERFIELD, Ill., Nov. 1, 2011 /PRNewswire/ --Takeda Global Research & Development Center, Inc., (Takeda) announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

Currently, the FDA is reviewing the new drug applications (NDA) for the investigational therapies, which were resubmitted on July 25, 2011; the FDA has categorized these as Class 2 responses, requiring up to six months for review.Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the United States (U.S.) for the treatment of type 2 diabetes as an adjunct to diet and exercise.Discovered by Takeda San Diego, Inc., alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play a role in regulating blood glucose levels. Pioglitazone was approved in 1999 for the treatment of type 2 diabetes as an adjunct to diet and exercise. If approved, alogliptin/pioglitazone will be the first type 2 diabetes treatment option in the U.S. to include both a DPP-4 inhibitor and a thiazolidinedione (TZD) in a single tablet.

According to the International Diabetes Federation, a staggering 285 million individuals were living with diabetes worldwide in 2010.

"As recent figures indicate that diabetes continues to be a serious global health challenge, Takeda remains deeply committed to researching new and important therapeutic options for patients living with type 2 diabetes," said David Recker, M.D., senior vice president, clinical science, Takeda Global Research & Development Center. "Phase 3 studies have demonstrated that the combination of a'/>"/>

(Date:3/3/2015)... BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company ... to address unmet needs in large, well-defined and underserved ... executive officer and co-founder of BioPharmX, will present at ... on Wednesday, March 11 at 9:00 a.m. PDT at ... Dana Point , California. ...

(Date:3/3/2015)... , March 3, 2015 UnaliWear announces the market ... support for seniors that guards against wandering and provides ... The new wearable – the Kanega watch ( http://www.UnaliWear.com ... to use an easy speech interface rather than buttons, ... without human input. The watch goes ...

(Date:3/3/2015)... -- American Biosurgical, LLC ("ABI") ( www.americanbiosurgical.com ) a ... in the design, development and production of innovative ... device companies has announced the acquisition of MTI ... cable manufacturer based in North Carolina. The new ... name MTI Medical Cables. The ...

(Date:3/3/2015)... US Air Purifiers LLC , an Illinois ... pleased to announce that all Rabbit brand air purifiers are ... the west coast port strikes. This news comes just in ... , The port strikes, which have caused significant ... economic growth by as much as 1%, have hindered the ...

(Date:3/3/2015)... it is clear that the prospect of reduced premiums ... signing up to UBI policies, more mature audiences may ... to current regulations, the application of UBI in Canada ... capability is starting to be realised in the US ... are at the top of the value-added services wish-list. ...

(Date:3/3/2015)... York, NY (PRWEB) March 03, 2015 Daylight ... this spring. Sanjeev Kothare, MD, has tips for parents. , ... come March 8 at 2:00 a.m. when they set their ... when you wake up that day -- one hour earlier ... , That’s why parents should start thinking about “sleep hygiene” ...

(Date:3/3/2015)... The first week of March is Sleep ... event brings recognition to a rarely discussed problem that ... to the Centers for Disease Control , 70 million ... another. Too little or unrestful sleep is associated with ... depression, and even a higher likelihood of obesity. ...

... OAK BROOK, Ill. A new calcium scoring method may ... a new multicenter study published in the June issue of ... only the amount of calcified plaque build-up in the coronary ... the location of the calcium in the arteries is particularly ...

... summer days ahead and the,delights of a good book ... "Lifeliner: The Judy Taylor story," the debut book from ... inspiring summer read, it tells the poignant story of ... first person to live,decades on intravenous feeding without eating ...

... Nearly half of patients with a history of heart disease ... and do not perceive themselves to have an elevated cardiovascular ... of Archives of Internal Medicine, one of the JAMA/Archives journals. ... times the risk of having a heart attack or dying ...

... DALLAS May 26, 2008 Adding noninvasive imaging ... are at risk of developing heart disease, UT Southwestern ... from the UT Southwestern-led Dallas Heart Study to determine ... for calcium deposits and blockages could identify more people ...